Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Precision radiation may better control spine tumors without extra risk

NCT ID NCT07656883

Disease control Sponsor: Institut Cancerologie de l'Ouest Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests a highly targeted radiation technique called stereotactic body radiotherapy (SBRT) against standard radiotherapy for people whose cancer has spread to the spine but has not yet compressed the spinal cord. The goal is to see if SBRT can better prevent tumor growth and spinal cord complications while keeping side effects low. Participants receive either standard radiation or SBRT over five sessions, with close monitoring for safety and tumor control.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Stereotactic Body Radiotherapy (SBRT)
What this could lead to
If successful, this precise radiation approach could offer better long-term control of spinal tumors, reducing pain and preventing spinal cord compression.
What could go wrong
This is a mid-stage trial; the higher radiation dose may increase risk of vertebral fractures or spinal cord injury, and benefits over standard care are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 167 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Oct 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed solid tumor; * Vertebral bone metastasis located between C2 and S1 (inclusive) with epiduritis (spinal cord or cauda equina) without clinical and/or radiological spinal cord compression on MRI; * Performance status (PS) ≤ 1; * Spinal Instability Neoplastic Score (SINS) ≤12; * Patient has been informed and has provided freely given, written, and signed informed consent; * Patient is affiliated with or a beneficiary of the national health insurance system. Exclusion Criteria: * Neurological deficit attributable to spinal cord compression or cauda equina syndrome; * Patient experiencing pain that prevents lying down for 30 minutes despite optimal analgesic treatment; * Life expectancy ≤6 months as estimated by the investigator; * Neurosurgical indication (preventive or decompressive) prior to radiotherapy; * More than one epiduritis lesion requiring treatment; * Prior surgery on the same vertebra targeted in the protocol; * Epiduritis and/or bone lesion extending over more than three contiguous vertebral levels; * Previous irradiation of the spine with cumulative dose with cumulative spinal cord dose EQD2 \>50 Gy, α/β = 2; * Contraindication to MRI; * Pregnant or breastfeeding woman; * Patient under legal protection, guardianship, or unable to provide informed consent; * Inability to comply with study follow-up due to geographic, social, or psychological reasons.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epiduritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metastatic carcinoma in the bone Spinal Cord Compression

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Epiduritis Vertebral bone metastasis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    14 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHD Vendée

    La Roche-sur-Yon, 85000, France

  • CLCC Ste Catherine - Institut du cancer Avignon/Provence

    Avignon, 84918, France

  • Centre Gillaume le Conquérant

    Le Havre, 76600, France

  • Centre Henri Becquerel

    Rouen, 76038, France

  • Chru Bretonneau

    Tours, 37044, France

  • Chu de Brest

    Brest, 29200, France

  • Clinique Saint Yves

    Vannes, 56000, France

  • Clinique Victor Hugo

    Le Mans, 72000, France

  • Clinique de la Côte d'Emeraude

    St-Malo, 35400, France

  • Clinique mutualiste de l'Estuaire

    Saint-Nazaire, 44600, France

  • Groupe Hospitalier Bretagne Sud (GHBS)

    Lorient, 56322, France

  • Institut de Cancerologie de L'Ouest

    Angers, 49055, France

  • Institut de Cancérologie Radiothérapie Bretillien (ICRB)

    Rennes, 35760, France

  • Institut de Cancérologie de l'Ouest

    Saint-Herblain, 44805, France